Endocrine Abstracts

Objectives: It is known that the obesity and insulin resistance are an integral part of acromegaly. The aim of study was to evaluate the role of octreotide LAR treatment on BMI in patients with acromegaly.

Methods: Sixteen patients with acromegaly diagnosed at Endocrinology Clinic in Sarajevo (10 females and 6 males, mean age 53.4±6.3 years, age range 38–65 years, six patients with microadenoma and 10 patients with macroadenoma) were treated with octreotide. Follow-up period was 3 years (2009–2013). Nine patients were treated with surgical and octreotide treatment. One patient was treated with surgical, octreotide and gamma-knife treatment and six patients were treated only with octreotide LAR. Five patients were diabetics. Anthropometric measurements (including height, weight, BMI and waist), concentration of human GH (hGH), IGF1, CRP, blood glucose, basal insulin and lipid profile were evaluated before treatment and every 6 months during follow-up period of 3 years, while magnetic resonance imaging (MRI) was taken before the treatment and every year during treatment. Thirteen patients received octreotide 30 mg/28 days, one patient received 20 mg and other two 60 mg/28 days.

Results: Octreotide LAR significantly reduced GH (50.13±22.44 vs 2.11±0.56 ng/ml), IGF1 (749.54±112.48 vs 337.33±83.54 ng/ml), adenoma size and CRP (4.56±1.34 vs 2.34±1.01 mg/l) and non-significantly reduced level of basal insulin and cholesterol. During follow-up period octreotide LAR treatment significantly reduced dosage of exogenous insulin at diabetics (−43%). Regression analyses showed inverse association of octreotide treatment and BMI (P<0.01).

Conclusions: Treatment with octreotide LAR in acromegaly significantly reduced BMI, GH, IGF1 and CRP. As well this treatment reduced dosage of exogenous insulin at acromegalic patients with diabetes.